Pulse Biosciences posts investor deck with nsPFA cath lab study details and 2026 goals

PULSE BIOSCIENCES, INC.

New details disclosed on pivotal clinical study of nsPFA Cardiac Catheter for atrial fibrillation.
Next-generation nPulse cardiac catheter under development described in the deck.
2026 corporate goals summarized across electrophysiology, cardiac surgery, and soft tissue ablation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.